agents and antineoplastic agents
`Mittmann, Ulrich; Sachetto, Jean-Pierre
`INVENTOR(S):
`Tillotts Pharma AG, Switz.
`PATENT ASSIGNEE(S):
`PCX Int. Appl., 33 pp.
`SOURCE:
`CODEN: PIXXD2
`Patent
`DOCUMENT TYPE:
`English
`LANGUAGE:
`1
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`APPLICATION NO.
`DATE
`PATENT NO.
`KIND DATE
`20050615
`WO 2005-EP6413
`WO 2005123061
`20051229
`A1
`BY, BZ, CA, CH,
`AZ, BA, BB, BG, BR, BW,
`W: AE, AG, AL, AM, AT, AU,
`ES, FI, GB, GD,
`CN, CO, CR, CU, CZ, DE,
`DK, DM, DZ, EC, EE, EG,
`KM, KP, KR, KZ,
`IL, IN, IS, JP, KE, KG,
`GE, GH, GM, HR, HU, ID,
`LV, MA, MD, MG, MK, MN,
`LC, LK, LR, LS, LT, LU,
`MW, MX, MZ, NA,
`SD, SE, SG, SK,
`PH, PL, PT, RO, RU, SC,
`NG, NI, NO, NZ, OM, PG,
`UZ, VC, VN, YU,
`TR, TT, TZ, UA, UG, US,
`SL, SM, SY, TJ, TM, TN,
`ZA, ZM, ZW
`RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD,
`SL,
`SZ,
`TZ,
`CY,
`AZ, BY, KG, KZ, MD, RU, TJ,
`TM,
`AT,
`BE,
`BG, CH,
`
`EE, ES, FI, FR, GB, GR, HU, IS, IT, LT, LU, MC, NL, PL, PT, IE,
`
`RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
`MR, NE, SN, TD, TG
`GB 2004-13730
`A 20040618
`PRIORITY APPLN. INFO.:
`Entered STN: 30 Dec 2005
`ED
`salt
`AB
`Polyunsatd. fatty acid ("PUFA") or
`a pharmacol.
`acceptable
`at
`with
`thereof (such as EPA and/or DHA)
`is
`used in
`combination
`or a pharmacol.
`an immunosuppressive agent or an antineoplastic
`agent
`acceptable salt or derivative
`thereof in
`the
`treatment
`conditions
`of
`application of
`acutely or chronically inadequate
`immune response
`by
`topical
`said active agents to at least a
`portion
`of
`
`the mucosa. Specific intestinal
`
`conditions that may be treated
`include
`chronic
`inflammatory disease (e.g.
`Chrohn's disease and ulcerative
`colitis)
`and tumor
`disease
`(e.g. bowel cancer
`and prostate cancer). One advantage of preferred embodiments
`of
`the
`invention
`is that bioavailability of immunosuppressive
`or
`
`antineoplastic agents is
`increased. For example, capsules contained fish oil
`(over
`60%
`of
`DHA
`Incromega 3F60 EPA), Eudragit NE 30D coating, polysorbate
`80.
`REFERENCE COUNT:
`THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
`10
`RECORD. ALL CITATIONS AVAILABLE
`IN THE
`RE
`HCAPLUS COPYRIGHT 2006 ACS on STN
`2005:1355507 HCAPLUS Full-text
`144:74884
`A pharmaceutical compositions containing
`polyunsaturated fatty acids in
`combination
`immunosuppressive agents and antineoplastic
`Mittmann, Ulrich; Sachetto, Jean-Pierre
`INVENTOR(S):
`Tillotts Pharma AG, Switz.
`PATENT ASSIGNEE (S) :
`PCT Int. Appl., 33 pp.
`SOURCE:
`CODEN: PIXXD2
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`PATENT NO.
`WO 2005123060
`
`L139 ANSWER 60 OF 73
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`
`KIND
`A1
`
`DATE
`20051229
`
`APPLICATION NO.
`WO 2005-EP6412
`
`DATE
`20050615
`
`UG,
`
`ZM,
`CZ,
`
`or
`
`FORMAT
`
`with
`agents
`
`0198
`
` EXHIBIT 1005 (PART 2 OF 3)
`
`

`

`W: AE, AG, AL, AM, AT,
`BA, BB, BG, BR, BW, BY, BZ, CA,'CH,
`AU, AZ,
`CN, CO, CR, CU, CZ,
`DM, DZ, EC, EE, EG, ES, FI, GB, GD,
`DE, DK,
`GE, GH, GM, HR, HU,
`IN, IS, JP, KE, KG, KM, KP, KR, KZ,
`ID, IL,
`LU, LV,
`LC, LK, LR, LS, LT,
`MA, MD, MG, MK, MN, MW, MX, MZ, NA,
`NG, NI, NO, NZ, OM,
`PL, PT, RO, RU, SC, SD, SE, SG, SK,
`PG, PH,
`SL, SM, SY, TJ, TM,
`TT, TZ, UA, UG, US, UZ, VC, VN, YU,
`TN, TR,
`ZA, ZM, ZW
`NA, SD, SL, SZ, TZ, . UG, ZM, ZW, AM,
`RW: BW, GH, GM, KE, LS,
`MW, MZ,
`TM, AT, BE, BG, CH, CY, CZ, DE, DK,
`RU, TJ,
`AZ, BY, KG, KZ, MD,
`GR, HU,
`IE, IS, IT, LT, LU, MC, NL, PL, PT,
`EE, ES, FI, -FR, GB,
`
`CF, CG, CI, CM, GA, GN, GQ, GW, ML,
`RO, SE, SI, SK, TR,
`BF, BJ,
`MR, NE, SN, TD, TG
`GB 2004-13729
`A 20040618
`PRIORITY APPLN. INFO.:
`Entered STN: 30 Dec 2005
`ED
`or
`salt
`AB
`Polyunsatd. fatty acid ("PUFA") or
`a pharmacol.
`acceptable
`of
`thereof (such as EPA and/or DHA) is used in combination with at least one
`an immunosuppressive agent or an antineoplastic
`agent or
`a Pharmacol,
`acceptable salt or derivative thereof
`in the
`treatment
`of
`conditions
`acutely or chronically inadequate immune response
`by
`topical
`application
`
`said active agents to at least a portion of the intestinal mucosa. Specific
`conditions that may be treated include chronic inflammatory disease (e.g.
`Chrohn's disease and ulcerative colitis)
`
`and disease (e.g. bowel cancer tumor
`
`and prostate cancer). One advantage of preferred embodiments of
`the invention
`is that bioavailability of immunosuppressive
`or
`antineoplastic
`agents
`is
`increased. For example, capsules contained fish
`oil
`(over
`60%
`of
`DHA
`Incromega 3F60 EPA), Eudragit NE 30D
`
`coating, polysorbate 80.
`REFERENCE COUNT:
`9
`THERE ARE 9 CITED REFERENCES AVAILABLE
`FOR THIS
`
`RECORD. ALL CITATIONS AVAILABLE IN THE FORMAT RE
`
`HCAPLUS COPYRIGHT 2006 ACS on STN
`L139 ANSWER 61 OF 73
`ACCESSION NUMBER:
`2005:1223775 HCAPLUS Full-text
`DOCUMENT NUMBER:
`143:483122
`TITLE:
`Methods and articles for the
`of drugs
`delivery
`eye for the treatment of posterior
`
`segment diseases
`INVENTOR(S):
`Schultz, Clyde
`PATENT ASSIGNEE(S):
`Directcontact LLC, USA
`SOURCE:
`U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.
`Ser. No. 971, 997 .
`CODEN: USXXCO
`DOCUMENT TYPE:
`Patent
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`2
`PATENT INFORMATION:
`PATENT NO.
`US 2005255144
`US 2005208102
`US 2005074497
`PRIORITY APPLN. INFO.:
`
`APPLICATION NO.
`DATE
`US
`20050409
`2005-102454
`US
`2004-821718
`20040409
`US.
`2004-971997
`20041022
`2003-461354P
`US
`P 20030409
`2004-821718
`US
`A2 20040409
`US
`2004-971997
`A2 20041022
`Entered STN: 18 Nov 2005
`drug
`delivery
`for
`methods
`This invention provides articles and
`
`treatment posterior segment of
`hydrogel containing one or more drugs
`for the
`
`disease and/or dry eye conditions. Exemplary drugs are anti-angiogenesis
`compds. for the treatment of macular
`
`degeneration. Allowing passive
`transference of this drug from a dilute solution into the hydrogel produces
`the delivery system. The hydrogel, when placed in contact with the eye,
`delivers the drug. The delivery of the drug is sustained
`over
`an
`'
`extended
`
`.
`
`ED
`AB
`
`KIND DATE
`20051117
`A1
`20050922
`A1
`A1
`20050407
`
`derivative
`
`to
`
`the"
`
`including
`a
`
`0199
`
`

`

`eye, which is
`
`period of time, which is of particular utility in the
`periodically flushed with tears. This sustained delivery accelerates
`the
`of localized
`treatment process while avoiding
`potential damaging
`effects
`delivery of high concns. of
`compds., e.g., from
`eye
`drops.
`
`'
`
`L139 ANSWER 62 OF 73
`HCAPLUS COPYRIGHT 2006 ACS on STN
`ACCESSION NUMBER:
`2005:983601 HCAPLUS Full-text
`DOCUMENT NUMBER:
`143:272523
`containing
`Stable ophthalmic oil-in-water emulsions
`TITLE:
`eye
`sodium hyaluronate for alleviating dry
`INVENTOR(S):
`Yu, Zhi-Jian; Huth, Stanley W.; Crawford, Lauren L.;
`Cook, James N.
`PATENT ASSIGNEE(S) :
`USA
`SOURCE:
`U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.
`Ser. No. 802,153.
`CODEN: USXXCO
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`3
`PATENT INFORMATION:
`PATENT NO.
`DATE
`APPLICATION NO.
`20050404
`US 2005-98827
`US 2005196370
`US 2004185068
`20030318
`US 2003-392375
`US 2004191284
`US 2004-802153
`20040317
`A2 20030318
`US 2003-392375
`PRIORITY APPLN. INFO.:
`US 2004-802153
`A2 20040317
`Entered STN: 09 Sep 2005
`ED
`AB
`
`
`contain demulcent for the a
`Stable oil-in-water emulsions are described which
`treatment of dry eye such
`
`as sodium hyaluronate. The oil-in-water emulsions
`lens
`are stable and have anti-microbial activity sufficient
`for
`use as
`contact
`WSCP
`disinfecting solns. Thus, an emulsion contained sodium
`chlorite
`65
`and
`ppm, sodium hyaluronate 0.1, castor oil
`1.25,
`ethoxylated
`hydrogenated
`oil. 1, boric acid 0.6, sodium
`borate decahydrate
`0.035,
`calcium
`chloride
`. dihydrate 0.006, MgC12.6H20
`0.006, KC1 0.14,
`NaCl
`3.5,
`and
`water
`
`KIND DATE
`20050908
`A1
`20040923
`A1
`20040930
`A1
`
`L139 ANSWER 63 OF 73
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`INVENTOR(S):
`PATENT ASSIGNEE(S):
`SOURCE:
`. DOCUMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`PATENT NO.
`WO 2004091578
`WO 2004091578
`WO 2004091578
`
`HCAPLUS COPYRIGHT 2006 ACS on STN
`2004:902155 HCAPLUS Full-text
`141:384286
`Novel encochleation methods, cochleates
`and
`use
`Mannino, Raphael J.; Gould-Fogerite,
`Susan;
`Krause-Elsmore, Sara L.; Delmarre, David;
`Biodelivery Sciences International, Inc.,
`University of Medicine and Dentistry
`of
`PCT Int. Appl., 195 pp.
`•
`CODEN: PIXXD2
`Patent
`English
`3
`
`KIND
`A2
`CI
`A3
`
`DATE
`20041028
`20050127
`20050331
`
`APPLICATION NO.
`WO 2004-US11026
`
`DATE
`20040409
`
`methods
`
`of
`
`Lu,
`USA;
`New
`
`Ruying
`Jersey
`
`0200
`
`

`

`W:
`
`AE, AG, AL, AM,
`AT, AU, AZ,
`BY, BZ, CA, CH,
`BA, BB, BG> BR, BW,
`CN, CO, CR, CU,
`ES, FI, GB, GD,
`DM, DZ, EC, EE, EG,
`CZ, DE, DK,
`GE, GH, GM, HR,
`IN, IS, JP, KE, KG,
`HU, ID, IL,
`KP, KR, KZ, LC,
`LK, LR, LS, LT,
`LU, LV, MA,
`MX, MZ, NA, NI,
`MD, MG, MK, MN, MW,
`NO, NZ, OM, PG,
`RO, RU, SC, SD,
`SE,
`PH, PL, PT,
`SG, SK, SL, SY,
`TJ, TM, TN, TR,
`UG, US, UZ, VC, VN,
`TT, TZ, UA,
`YU, ZA, ZM, ZW
`RW: BW, GH, GM, KE,
`ZM, ZW, AM, AZ,
`SD, SL, SZ, TZ, UG,
`LS, MW, MZ,
`BY, KG, KZ, MD,
`RU, TJ, TM,
`CZ, DE, DK, EE,
`AT, BE, BG, CH, CY,
`ES, FI, FR, GB,
`PT, RO, SE, SI,
`IT, LU, MC, NL, PL,
`GR, HU, IE,
`SK, TR, BF, BJ,
`CF, CG, CI,
`CM, GA, GN, GQ, GW,
`ML, MR, NE, SN,
`TD, TG
`US 2005013854
`US 2004-822230
`A1
`20050120
`20040409
`EP 1624858
`A2
`EP 2004-759375
`20060215
`20040409
`R *
`AT, BE, CH, DE,
`GB, GR, IT, LI, LU,
`DK, ES, FR,
`NL, SE, MC, PT,
`IE, SI, FI, RO,
`CY, TR, BG,
`CZ, EE, HU, PL, SK
`PRIORITY APPLN. INFO.:
`US 2003-461483P
`P 20030409
`US 2003-46307 6P
`P 20030415
`US 2003-499247P
`P 20030828
`US 2003-502557P
`P 20030911
`US 2003-532755P
`P 20031224
`P 20040115
`US 2004-537252P
`P 20040324
`US 2004-556192P
`W 20040409
`WO 2004-US11026
`Entered STN: 28 Oct 2004
`relates
`The invention generally
`to
`cochleate drug
`delivery
`vehicles.
`making
`are novel methods
`for
`cochleates
`and
`cochleate
`compns.
`introducing a cargo
`moiety
`to
`liposome
`in
`the
`a
`presence
`Also
`disclosed are cochleates
`and
`cochleate
`compns.
`that
`include
`cochleates
`Addnl., anhydrous
`that
`inhibitor, and optionally,
`a cargo
`moiety.
`include a protonized
`cargo
`
`moiety, divalent metal cation a
`
`and
`a
`neg.
`charge
`lipid are disclosed. Methods of using the
`cochleate
`compns.
`of
`the
`including methods of
`administration,
`are
`also
`
`disclosed. •
`
`ED
`AB
`
`STN
`
`using
`disease
`a
`DMARD
`with
`David;
`Peach,
`
`U.S. Pat. Appl. Publ., 189 pp., Cont.-in-part U.S. of
`
`
`
`INVENTOR(S):
`PATENT ASSIGNEE(S):
`SOURCE:
`
`L139 ANSWER 64 OF
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`
`73
`on
`HCAPLUS COPYRIGHT 2006 ACS
`2004:100508 HCAPLUS Full-text
`140:157440
`Methods for treating
`an
`autoimmune
`soluble CTLA4 molecule
`in
`combination
`NSAID
`Cohen, Robert; Carr,
`Suzette;
`Hagerty,
`Robert J.; Becker,
`Jean-Claude
`USA
`
`Ser. No. 898,195.
`CODEN: USXXCO
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`2
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`PATENT NO.
`APPLICATION NO.
`US 2004022787
`US 2003-419008
`US 2003083246
`US 2001-898195
`PRIORITY APPLN. INFO.:
`US 2000-215913P
`US 2001-898195
`ED
`Entered STN:
`08 Feb 2004
`AB
`to
`compns.
`The present invention
`relates
`system diseases such
`as
`rheumatic
`disease,
`
`KIND
`A1
`A1
`
`DATE
`20040205
`20030501
`
`DATE
`20030418
`20010702
`P 20000703
`A2 20010702
`and treating immune methods
`
`
`by
`administering
`
`for
`
`0201
`
`

`

`endogenous
`
`block
`that
`mols.
`4)
`soluble CTLA4 (cytotoxic lymphocyte antigen T
`
`
`or
`alone,
`ligands,
`B7 (CD80) mols. from
`binding
`their
`other agents including
`disease
`modifying
`
`anti-rheumatic (DMARDs) or non­drugs
`
`steroidal anti-inflammatory
`drugs
`
`(NSAIDs). The soluble CTLA4
`mol.
`comprises
`the extracellular domain
`(residues
`1-124)
`of
`full-length
`may be fused at the N-terminus
`with
`the
`signal
`
`peptide M and at
`of
`the C-terminal end
`with
`
`an constant region. Single-site Igyl
`
`and
`double-site
`CTLA4 mutant sequences
`are also
`constructed,
`including
`L104E/A29Y-CTLA4/Ig,
`L104E/A2 9L-CTLA4/Ig, L104E/A29T-CTLA4/Ig,
`and
`
`L104E/A29W-CTLA4/Ig. CTLA4/Ig
`administered at 10
`mg/kg
`(plus
`methotrexate)
`has
`superior
`treatment of rheumatoid
`arthritis
`
`compared to placebo (plus
`methotrexate)
`based on efficacy
`parameters
`of
`the
`American
`Collage
`of
`CD80,
`Binding kinetics
`to
`CD86
`and
`Set and Response Definitions
`(ACR).
`pharmacokinetics, and
`pharmacodynamics
`of
`C-reactive
`protein,
`factor, interleukin-2
`receptor,
`
`interleukin and tumor necrosis -6,
`
`factor
`a
`are provided.
`•
`
`human
`
`STN
`
`on
`HCAPLUS COPYRIGHT 2006 ACS
`OF 73
`L139 ANSWER 65
`
`2002:9767 HCAPLUS Full-text
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`136:74627
`Drug compositions containing cyclosporin and
`TITLE:
`their application as
`topical
`systems
`Wohlrab, Johannes;
`Neubert,
`Reinhard;
`Germany
`Ger. Offen., 14 pp.
`CODEN: GWXXBX
`Patent
`German
`1
`COUNT:
`
`INVENTOR(S):
`PATENT ASSIGNEE (S) :
`SOURCE:
`DOCUMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM.
`PATENT INFORMATION:
`PATENT NO.
`DATE
`KIND
`APPLICATION NO.
`DATE
`DE 2000-10029404
`20000615
`DE 10029404
`20020103
`A1
`CA 2001-2470230
`20011214
`CA 2470230
`20030626
`AA
`A1
`WO 2001-EP14749
`20011214
`20030626
`WO 2003051385
`W:
`AE, AG, AL,
`BZ, CA, CH, CN,
`AM, AT, AU, AZ, BA, BB, BG, BR, BY,
`CO, CR, CU,
`GB, GD, GE, GH,
`CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
`KZ, LC, LK, LR,
`GM, HR, HU,
`
`ID, IL, IN, IS, JP, KE, KG, KP, KR,
`LS, LT, LU,
`NO, NZ, OM, PH,
`LV, MA, MD, MG, MK, MN, MW, MX, MZ,
`PL, PT, RO,
`RU, SD, SE, SG, SI, SK,
`SL,
`TJ,
`TM,
`TN, TR, TT, TZ,
`UA, UG, US,
`UZ, VN, YU, ZA, ZM, ZW
`RW: GH, GM, KE,
`LS, MW, MZ, SD,
`
`SL, SZ, UG, ZM, ZW, AM, AZ, BY, TZ,'
`
`KG, KZ, MD,
`
`RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
`GR, IE, IT,
`LU, MC, NL, PT, SE, TR, BF, BJ,
`CF, CG, CI, CM, GA,
`
`GN, GQ, GW,
`ML, MR, NE, SN, TD, TG
`AU 2002231703
`AU 2002-231703
`A1
`20011214
`20030630
`EP 1455810
`.
`A1
`EP 2001-991845
`20011214
`20040915
`AT, BE, CH,
`DE, DK, ES, FR, GB, GR, IT, LI,
`LU,
`
`NL, MC, PT,
`IE, SI, LT,
`LV, FI, RO, MK, CY, AL, TR
`20011214
`BR 2001017197
`A
`BR 2001-17197
`20041214
`CN 1582161
`A
`CN 2001-823950
`20011214
`20050216
`US 2005106189
`US 2003-498656
`20050519
`A1
`20011214
`JP 2005516931
`JP 2003-552318
`20050609
`T2
`20011214
`NZ 2001-534061
`NZ 534061
`20060127
`A
`20011214
`NO 2004-3001
`NO 2004003001
`20040914
`A
`20040713
`DE 2000-10029404
`PRIORITY APPLN. INFO.:
`A 20000615
`WO 2001-EP14749
`W 20011214
`ED
`Entered STN: 04 Jan 2002
`
`Jahn,
`
`Konstanze
`
`SE,
`
`0202
`
`

`

`AB
`
`USA
`
`KIND
`
`cyclosporin
`the
`for
`containing
`emulsions
`The invention concerns
`digestion
`of
`the
`mucosa
`and
`the
`diseases of the skin
`The
`transplant
`organ
`of
`the
`prophylaxis
`bronchi, eye: and for
`The emulsions are
`e.g.
`corticosteroids,
`compns. can also
`contain
`other
`drugs,
`phase 1-10;
`surfactants
`composed of (weight/weight%):
`lipophilic
`cyclosporin
`Thus an
`other
`drugs
`0.1-20.
`hydrophilic phase
`40-80;
`and
`cyclosporin
`A
`2.0; 02 8.0;
`emulsion contained
`(weight/weight!):
`Tagat
`
`isopropylpalmitate
`Synperonic PE/L101
`12.0;
`5.0;
`
`propylene glycol water
`24.3.
`2
`THERE ARE 2 CITED
`REFERENCES
`AVAILABLE
`FOR
`REFERENCE COUNT:
`RECORD. ALL CITATIONS
`AVAILABLE
`IN
`THE
`HCAPLUS COPYRIGHT 2006 ACS
`on
`STN
`OF
`L139 ANSWER 66
`73
`2000:741944 HCAPLUS Full-text
`'
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`133:301214
`cyclosporin-
`Eye disorders treatment
`with
`TITLE:
`A derivatives
`INVENTOR(S):
`Garst, Michael E.
`PATENT ASSIGNEE(S):
`Allergan Sales, Inc.,
`PCT Int. Appl., 32
`pp.
`SOURCE:
`CODEN: PIXXD2
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`
`FAMILY ACC. NUM. COUNT: 1
`PATENT INFORMATION:
`APPLICATION NO.
`PATENT NO.
`DATE
`WO 2000-US8877
`WO 2000061168
`20001019
`A1
`CH,
`
`AT, AU, AZ, BA, BB, BG, BR, BY, CA,
`W: AE, AL, AM,
`ID,
`GE,
`GH,
`ES, FI, GB, GD,
`GM,
`DE, DK, EE,
`LV,
`
`KP, KR, KZ, LC, LK, LR, LS, LT, LU,
`JP, KE, KG,
`SI,
`NO, NZ, PL, PT, RO, RU, SD, SE, SG,
`MN, MW, MX,
`BY,
`UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
`TM, TR, TT,
`RU, TJ, TM
`BE,
`LS, MW, SD, SL,
`
`
`SZ,
`TZ, ZW, AT, UG,
`RW: GH, GM, KE,
`SE,
`
`
`LU, NL, PT, MC,
`IT,
`FR, GB, GR, IE,
`DK, ES, FI,
`GA, GN, GW, ML, MR, NE, SN, TD, TG
`CG, CI, CM,
`20010703
`US 1999-290833
`B1
`US 6254860
`CA 2000-2369457
`AA
`20001019
`CA 2369457
`EP 2000-921645
`20020109
`A1
`EP 1169050
`CH,
`NL,
`DE, DK, ES, FR, GB, GR, IT, LI, LU,
`BE,
`R: AT,
`IE, SI, LT,
`LV, FI, RO
`20021203
`JP 2000-610500
`JP 2002541207
`T2
`AU 759753
`B2
`20030501
`AU 2000-41935
`A
`NZ 514105
`NZ 2000-514105
`20050128
`A1
`20011101
`US 2001036449
`US 2001-870256
`20020226
`US 6350442
`B2
`US 1999-290833
`PRIORITY APPLN. INFO.:
`WO 2000-US8877
`MARPAT 133:301214
`OTHER SOURCE(S):
`Entered STN: 20 Oct 2000
`ED
`e.g.,
`eye,
`an
`in
`A method of treating
`a
`disorder
`AB
`state, phacoanaphylactic
`endophthalmitis, or uveitis, is provided. The method
`generally includes
`administering
`a
`therapeutically
`effective
`cyclosporin A derivative
`The derivative may
`be
`topically
`to
`the
`affected
`eye.
`administered as a solution,
`suspension
`or
`ointment pharmaceutically
`
`in
`acceptable excipient. Sixteen rabbits, 32
`eyes
`injected
`intravitreally
`are
`day 1 with 500 ^g
`of. human serum albumin. Eight
`
`rabbits receive no treatment.
`nL
`The other rabbits
`received
`10 of 2% ((R)-(Cyclo)alkylthio-Sar)3-(4 ' -
`
`
`DATE
`20000404
`CN, CU, CZ,
`IL, IN, IS,
`HR, HU,
`MD, MG, MK,
`SK, SL, TJ,
`KG, KZ, MD,
`CH, CY, DE,
`BF, BJ, CF,
`19990413
`20000404
`20000404
`SE, MC, PT,
`20000404
`20000404
`20000404
`20010530
`A 19990413
`W 20000404
`
`THIS
`RE
`
`an
`amount
`
`0203
`
`

`

`RE
`
`using
`
`heat
`
`A in
`hydroxy-MeLeu)4-cyclosporin
`4
`olive
`oil topically to both eyes applied
`
`
`after
`h
`times daily beginning
`1
`
`albumin The degree of intraocular injection.
`
`graded clin.
`inflammation produced
`was
`3
`
`times A marked
`a
`week
`difference in clin. severity
`of
`inflammation
`between
`eyes
`cyclosporin A derivative
`and control eyes was found.
`6
`REFERENCE COUNT:
`THERE ARE 6 CITED REFERENCES AVAILABLE
`THIS
`FOR
`RECORD. ALL CITATIONS
`AVAILABLE
`IN
`THE
`L139 ANSWER 67 OF
`73
`HCAPLUS COPYRIGHT 2006 ACS
`on
`STN
`ACCESSION NUMBER:
`1999:487224 HCAPLUS Full-text
`131:125456
`DOCUMENT NUMBER:
`Method for treating inflammatory
`diseases
`•
`TITLE:
`shock proteins
`INVENTOR(S):
`Gelfand, Erwin W.; Haczku,
`
`Angela Francisca; Lukacs,
`Katalin Veronika
`PATENT ASSIGNEE(S):
`National Jewish Medical
`and
`Research
`Center,
`SOURCE:
`PCT Int. Appl., 69
`pp.
`CODEN: PIXXD2
`Patent
`DOCUMENT'TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`PATENT NO.
`APPLICATION NO.
`DATE
`KIND
`DATE
`WO 9937319
`WO 1999-US1421
`19990729
`19990122
`Al'
`W: AL, AM, AT,
`AU, AZ, BA, BB, BG, BR, BY, CA, CH,
`CU, CZ, DE,
`CN,
`JP, KE, KG,
`DK, EE, ES,
`IS,
`FI, GB, GE, GH, GM, HR, HU, ID, IL,
`MN, MW, MX,
`LC, LK, LR, LS, LT, LU, LV, MD, MG,
`KP, KR, KZ,
`MK,
`NO, NZ, PL,
`TJ,
`SL,
`PT, RO, RU, SD, SE, SG, SI,
`SK,
`TM, TR, TT,
`UA, UG, UZ,
`VN, YU, ZW
`RW: GH, GM, KE,
`LS, MW, SD, SZ, UG, ZW, AT, BE, CH,
`CY, DE, DK, ES,
`GR, IE, IT, LU, MC, NL, PT, SE, BF,
`FI, FR, GB,
`CF, CG, CI,
`BJ,
`GW, ML, MR, NE, SN, TD,
`TG
`CM, GA, GN,
`ZA 9900499
`19990722
`A
`ZA
`19990122
`1999-499
`CA 2318263
`19990729
`CA
`AA
`19990122
`1999-2318263
`AU 9923374
`19990122
`Al
`AU
`1999-23374
`19990809
`BR 9907228
`A
`BR
`1999-7228
`19990122
`20001024
`EP 1049483
`Al
`1999-903321
`19990122
`EP
`20001108
`R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU,
`SE, MC, PT,
`NL,
`SI,
`IE,
`LV, FI, RO
`LT,
`20010221
`TR 200002973
`T2
`2000-200002973
`19990122
`TR
`JP 2002509074
`2000-528300
`T2
`JP
`20020326
`19990122
`NO 2000003775
`2000-3775
`A
`NO
`2'0 0 0 0 7 21
`20000922
`US 2002006410
`US
`2001-932483
`Al
`20010817
`20020117
`PRIORITY APPLN. INFO.:
`US
`1998-12330
`A 19980123
`WO
`1999-US1421
`W 19990122
`Entered STN: 06 Aug 1999
`ED
`AB
`a from a disease associated with an mammal
`
`
`protect
`A method is provided
`to
`inflammatory
`inflammatory response
`and
`in
`particular
`from
`an
`characterized by eosinophilia,
`airway
`hyperresponsiveness,
`and/or a Th2-type
`heat
`immune response. The method includes
`administration
`a
`of
`to a mammal having
`such
`a
`
`disease. Formulations useful
`in
`the
`present
`are also disclosed.
`4
`REFERENCE COUNT:
`THERE ARE 4 CITED
`REFERENCES
`AVAILABLE
`FOR
`RECORD. ALL CITATIONS
`AVAILABLE
`IN RE FORMAT
`
`THE
`73
`HCAPLUS COPYRIGHT 2006 ACS
`on
`STN
`1997:278763 HCAPLUS Full-text
`126:255503
`
`L139 ANSWER 68 OF
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`
`USA
`
`method
`THIS
`
`0204
`
`

`

`containing
`
`hydrocarbonaceous
`-
`
`12
`
`pp.
`
`.
`
`.
`
`TITLE:
`Ophthalmic compositions
`carrier
`INVENTOR(S):
`Kang, Meng-Che
`PATENT ASSIGNEE(S) :
`Kang, Meng-Che, Taiwan
`SOURCE:
`Brit. UK Pat. Appl.,
`CODEN: BAXXDU
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`3
`PATENT INFORMATION:
`PATENT NO.
`DATE '
`APPLICATION NO.
`KIND
`DATE
`GB 2302018
`GB 1995-11983
`Al
`19970108
`19950613
`GB 2302018
`B2
`19990825
`US 5698533
`US 1994-280827
`A
`19940726
`19971216
`PRIORITY APPLN. INFO.:
`US 1994-280827
`A 19940726
`ED
`Entered STN: 01 May 1997
`•
`AB
`and
`
`80-99.99% hydrocarbonaceous carrier of a
`
`drug
`Compns. contain 0.01-20%
`
`30-100°.
`at Typical
`which is a semisolid at room
`temperature
`and
`melts
`
`carriers are petrolatum
`or
`
`lanolin. An emulsifier is optionally
`present.
`Suitable drugs for inclusion
`in
`the
`
`compns. Delivery to the are
`
`also
`eye is particularly
`in
`nebulized
`form. Compns. containing
`
`vitamin
`A
`and
`vitamin B12 as active
`ingredients
`are
`
`exemplified. An ophthalmic composition
`contained petrolatum
`94,
`camphor
`5,
`menthol
`1
`g,
`
`vitamin
`
`STN
`
`for
`
`mucosal
`
`applications
`
`L139 ANSWER 69 OF
`73
`on
`HCAPLUS COPYRIGHT 2006 ACS
`ACCESSION NUMBER:
`1996:359823 HCAPLUS Full-text
`DOCUMENT NUMBER:
`125:19006
`.
`TITLE:
`Improved topical
`carriers
`INVENTOR(S):
`Osborne, David W.
`PATENT ASSIGNEE(S):
`Virotex Corporation,
`USA
`SOURCE:
`PCT Int. Appl.,
`11
`pp.
`CODEN: PIXXD2
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`PATENT NO.
`KIND DATE
`APPLICATION NO.
`DATE
`WO 9609829
`Al
`19960404
`WO 1995-US12288
`19950926
`W: AU, CA, JP, KR
`LU,
`RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
`MC, NL, PT, SE
`AU 9537263
`Al
`19960419
`AU 1995-37263
`199.50926
`PRIORITY APPLN. INFO.:
`US 1994-313418
`A 19940927
`WO 1995-US12288
`W 19950926
`ED
`21 Jun 1996
`Entered STN:
`AB
`use
`for
`is
`claimed
`A topical semisolid
`composition
`
`suspended nonaq. matrix. The in
`comprises one or
`more
`hydrophilic
`polymers
`assist
`in
`composition may be
`
`combined .a therapeutic agent with
`
`to
`mucosal lesions.
`The active agent
`
`may
`be
`a anesthetic suitable local
`
`for
`treatment of canker
`sores
`or
`Behcet's
`
`syndrome, for treatment a
`
`
`cyclosporin A, or an antimicrobial
`of lichen planus, or
`or
`antifungal
`Thus, a formulation
`can
`be
`
`prepared contains 4-10% Carbopol, which
`
`4-10%
`Gantrez MS-955, 4-10%
`cellulose
`
`gum, 70-88% white petrolatum. and
`
`
`on
`
`healing
`corticosteroid
`agent.
`
`L139 ANSWER 70
`
`
`
`OF HCAPLUS COPYRIGHT 2006 ACS 73
`
`
`
`on
`
`STN
`
`0205
`
`

`

`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`
`1996:377098 HCAPLUS Full-text
`125:26262
`docosahexaenoic
`Eicosapentaenoic acid
`and/or
`autoimmune
`immunosuppressive therapy
`of
`INVENTOR(S):
`Yazawa, Kazuyoshi; Oono,
`Shigeaki;
`Ishioka,
`Misaki;
`Nakamura, Satoshi
`PATENT ASSIGNEE(S):
`.Kanagawa Kagaku Kenkyusho
`Kk,
`Japan
`SOURCE:
`Jpn. Kokai Tokkyo
`
`Koho, pp. 4
`CODEN: JKXXAF
`Patent
`DOCUMENT TYPE: .
`Japanese
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`
`
`
`acid
`
`eye
`
`diseases
`
`PATENT NO.
`APPLICATION NO.
`KIND
`DATE
`DATE
`JP 08092129
`19931008
`JP 1993-275999
`A2
`19960409
`PRIORITY APPLN. INFO.:
`19931008
`JP 1993-275999
`Entered STN: 29 Jun 1996
`ED
`AB
`Eicosapentaenoic acid
`and/or
`acid
`docosahexaenoic
`are
`
`immunosuppressive therapy
`of
`eye Thus, patients with diseases.
`autoimmune
`
`FK 506 or cyclosporin A
`uveitis were treated
`with
`the
`oral
`immunosuppressant
`combined with fish oil containing 6% eicosapentaenoic
`acid
`and
`docosahexaenoic acid
`with
`satisfactory
`results.
`
`claimed
`
`25%
`
`OF
`
`STN
`
`HCAPLUS COPYRIGHT 2006 ACS on
`L139 ANSWER 71
`73
`ACCESSION NUMBER:
`1996:209937 HCAPLUS Full-text
`124:242363
`DOCUMENT NUMBER:
`TITLE:
`Stable pharmaceutical
`lipid
`containing
`emulsions
`and emulsifiers and lecithins
`INVENTOR(S):
`Suzuki, Hidekazu; Yamazaki,
`
`Satoshi;
`Naito, Yoshikazu;
`Endo, Kenji; Oguma, Touru;
`Maeda,
`Makoto
`PATENT ASSIGNEE(S):
`Wakamoto Pharmaceutical
`Co.,
`Ltd.,
`Japan
`SOURCE:
`
`Can. Pat. Appl., 7 7 pp.
`'
`CODEN: CPXXEB
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`PATENT NO.
`DATE
`KIND DATE
`19960114
`19950710
`CA 2153553
`CA 1995-2153553
`AA
`US 5693337
`A
`19971202
`US 1995-500087
`19950710
`A1
`EP 700678
`EP 1995-110923
`19960313
`19950712
`IT
`R: DE, FR, GB,
`JP 08081360
`JP 1995-197896
`19960326
`A2
`19950712
`PRIORITY APPLN. INFO.:
`JP 1994-183045
`A 19940713
`Entered STN: 12 Apr 1996
`ED
`component,
`oil
`comprises
`(A)
`an
`AB
`A lipid emulsion
`which
`
`lecithin, wherein
`lecithin
`and/or
`soybean
`agent containing yolk
`
`a
`
`comprises
`citric
`acid pharmaceutically or
`the lipid emulsion further
`acceptable salt thereof
`and
`
`at one member selected least
`
`the
`group
`from
`consisting of methionine,
`phenylalanine,
`serine,
`histidine
`pharmaceutically acceptable
`salts
`thereof,
`provided
`that is does not
`simultaneously contain
`methionine
`and
`
`phenylalanine. The emulsion does
`not
`change of color
`and
`formation
`of
`oil
`drops associated
`due
`natural lecithin-containing
`lipid emulsions
`to
`the foregoing additives. The drug containing
`lipid
`emulsion
`is
`
`APPLICATION NO.
`
`oils
`
`and
`
`and
`
`the
`
`with
`also
`
`0206
`
`

`

`emulsion
`lipid
`foregoing
`the
`thus
`and
`in storage stability
`lotions
`drips,
`nasal
`drops,
`eye
`drugs such as injections,
`cosmetics
`or
`administration
`oral
`inhalants and drugs
`for
`in
`mL
`20
`fluorometholone
`of
`A solution of 0.012
`g
`to
`a
`of ethanol was added
`solution of 20
`mL
`hexane:ethanol (10:1)
`containing 0.54 g of yolk lecithin
`
`and
`and
`mixed,
`followed
`0.06 g of yolk phosphatidylethanolamine
`film. To the lipid film was
`
`added g of soybean 5.4
`
`solvent to obtain
`a lipid
`oil and 94 mL of
`2% glycerin
`aqueous
`
`solution by vigorous stirring followed
`
`through shaking to
`carry
`out
`preliminary
`emulsification. The preliminarily
`
`emulsified liquid was
`passed
`through
`
`microfluidizer 10 times under a pressure
`of 750 kg/cm2 to
`emulsify
`the
`liquid,
`the
`pH
`value liquid
`
`was adjusted to
`6.5-7.5
`to
`give
`a milk stock lipid emulsion. white
`
`
`
`of
`
`STN
`
`topical
`for
`Olejnik,
`Orest
`
`OF 73
`L139 ANSWER 72
`on
`HCAPLUS COPYRIGHT 2006 ACS
`ACCESSION NUMBER:
`1996:38846 HCAPLUS Full-text
`DOCUMENT NUMBER:
`124:66660
`TITLE:
`Lacrimal gland-specific
`emulsions
`application to ocular
`tissue
`INVENTOR(S):
`Ding, Shulin; Tien,
`Walter
`L.;
`PATENT ASSIGNEE (S) :
`Allergan, Inc., USA
`SOURCE:
`PCT Int. Appl., 27
`pp. •
`CODEN: PIXXD2
`Patent
`DOCUMENT TYPE:
`LANGUAGE:
`English
`FAMILY ACC. NUM. COUNT:
`1
`PATENT INFORMATION:
`PATENT NO.
`KIND DATE
`APPLICATION NO.
`DATE
`WO 9531211
`19951123
`19950517
`A1
`WO 1995-US6302
`AU,
`W: AM, AT,
`DK,
`EE, ES, FI,
`BB, BG, BR, BY, CA, CH, CN, CZ, DE,
`HU,
`GB, GE,
`LU,
`LV, MD, MG,
`JP, KE, KG, KP, KR, KZ, LK, LR, LT,
`MX,
`MN, MW,
`TJ, TT, UA,
`NO, NZ, PL, PT, RO, RU, SD, SE, SI,
`SK,
`US, UZ
`SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR,
`RW: KE, MW,
`GB, GR, IE, IT,
`NL,
`LU, MC,
`
`PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
`ML, MR, NE,
`SN, TD,
`TG
`US 5474979
`A
`19951212
`US 1994-243279
`19940517
`19951123
`CA 2190485
`19950517
`AA
`CA 1995-2190485
`20030415
`C
`CA 2190485
`19950517
`AA
`19951123
`CA 1995-2309033
`CA 2309033
`C
`20030826
`CA 2309033
`19951205
`AU 1995-26409
`19950517
`A1
`AU 9526409
`AU 693213
`19-980625
`B2
`EP 759773
`19970305
`A1
`EP 1995-921294
`19950517
`20010808
`EP 759773
`B1
`CH,
`R: AT, BE,
`LU, MC, NL, PT, SE
`DE, DK, ES, FR, GB, GR, IE, IT, LI,
`CN 1152876
`A
`19950517
`19970625
`CN 1995-194078
`19950517
`BR 9507664
`19971007
`A
`BR 1995-7664
`19950517
`JP 10500414
`T2
`19980113
`JP 1995-529895
`B2
`JP 3441462
`20030902
`EP 1044678
`20001018
`A1
`EP 2000-202069
`EP 1044678
`B1
`20030312
`R: AT, BE,
`CH,
`DE, DK, ES, FR, GB, GR, IT, LI, LU,
`AT 203911
`20010815
`E
`AT 1995-921294
`T3
`20011216
`ES 2161895
`ES 1995-921294
`20020228
`PT 759773
`T
`PT 1995-921294
`E
`20030315
`AT 234076
`AT 2000-202069
`JP 2003231646
`20030819
`JP 2003-63234
`A2
`
`19950517
`NL, SE, MC, PT, IE
`19950517
`19950517
`19950517
`19950517
`• 19950517
`
`0207
`
`

`

`PT 1044678
`ES 2194670
`CN 1288722
`HK 1034190
`GR 3036945
`PRIORITY APPLN. INFO.:
`
`T
`T3
`A
`A1
`T3
`
`20030829
`20031201
`20010328
`20051209
`20020131
`
`19950517
`2000-202069
`PT
`19950517
`ES
`2000-202069
`2000-120126
`20000714
`CN
`20010709
`2001-104710
`HK
`20011018
`GR
`2001-401814
`A 19940517
`US
`1994-243279
`CA
`A3 19950517
`1995-2190485
`EP
`A3 19950517
`1995-921294
`JP
`A3 19950517
`1995-529895
`WO
`W 19950517
`1995-US6302
`Entered STN: 20 Jan 1996
`
`the nonirritating form
`
`is disclosed
`in
`A pharmaceutical composition
`cyclosporin
`least
`one
`emulsion which includes
`at
`in admixt. with a higher
`cyclosporin
`fatty acid glyceride
`and polysorbate
`80. More particularly,
`
`the
`may be cyclosporins A and
`the
`higher
`fatty
`acid glyceride
`The composition allows
`a high
`comfort
`level
`and
`low irritation potential
`suitable for delivery.of
`medications
`to
`sensitive
`areas
`with enhanced absorption
`in
`the
`lacrimal
`gland. In addition, the
`composition
`has stability for up
`to
`9
`without
`
`crystallization For
`mo
`cyclosporin
`A
`example, an ophthalmic
`containing
`0.2,
`emulsion
`Polysorbate-80 1.0, Pemulen 0.05, glycerol
`2.2,
`
`NaOH q.s., and purified water
`to 100% was formulated
`to
`treat
`keratoconjunctivitis sicca.
`
`ED
`AB
`
`of
`
`may
`such
`
`L139 ANSWER 73
`ACCESSION NUMBER:
`DOCUMENT NUMBER:
`TITLE:
`
`AUTHOR(S) :
`CORPORATE SOURCE:
`SOURCE:
`
`STN
`
`73
`OF
`on
`HCAPLUS COPYRIGHT 2006 ACS
`1993:140090 HCAPLUS Full-text
`118:140090
`Effects of steroids and
`immunosuppressive drugs
`endotoxin-uveitis in
`rabbits
`Ohia, Ekanem 0.; Mancino, Michael;
`Kulkarni, Prasad S.
`Sch. Med., Univ. Louisville, Louisville, KY, USA
`Journal of Ocular
`Pharmacology
`(1992),
`8(4),
`CODEN: JOPHER; ISSN:
`8756-3320
`Journal
`DOCUMENT TYPE:
`English
`LANGUAGE:
`ED
`Entered STN: 13 Apr 1993
`cyclosporin
`AB
`(DEXA),
`dexamethasone
`of
`Anti-inflammatory actions
`intravitreal
`induced
`on
`uveitis
`by
`assessed
`rapamycin (RAPA)
`were
`In this model, endotoxin
`
`caused a
`at
`24
`h.
`rabbits
`endotoxin (100
`ng)
`in
`barrier
`(BAB)
`and
`polymorphonuclear
`breakdown of the
`blood-aqueous
`(PMN) infiltration
`into
`the
`aqueous
`humor
`(AH)
`and
`DEXA given i.m. (2
`mg/kg),
`but
`not
`topical
`DEXA (0.1% 6
`+ daily),
`inhibited
`AH
`leukocytes and protein
`level.
`
`However, routes caused an both
`
`inhibition
`of
`AH
`PGE2 and LTB4. In the ICB, i.m. DEXA
`
`inhibited PGE2 synthesis and
`myeloperoxidase (MPO)
`activity. Both i.m. CSA (25
`mg/kg)
`and
`i.m.
`RAPA
`mg/kg) inhibited the
`AH
`
`leukocytes protein content and MPO and
`
`activity
`ICB. RAPA also inhibited
`protein
`and
`
`eicosanoid AH LTB4) levels in (except
`
`both the AH and ICB. Interestingly, castor
`oil,
`a
`vehicle
`of
`inhibited AH leukocytes
`
`and the release of PGE2
`into
`
`AH from ICB. In and
`
`summary, systemic
`administration
`of
`DEXA
`and
`other
`in rabbits.
`(CSA and RAPA) inhibited
`endotoxin-induced
`uveitis
`
`on
`
`295-307
`
`in
`
`CSA,
`immunosuppressive
`
`0208
`
`

`

`FILE 'BIOSIS' ENTERED AT 16:26:29 ON 02 OCT 2006
`ACT GAR857BI1AU/A
`1)SEA ABB=ON PLU=ON CYCLOSPORIN A/CN
`44)SEA ABB=ON PLU=ON ACHEAMPONG A?/AU
`117)SEA ABB=ON PLU=ON TANG LIU D?/AU
`4672)SEA .ABB=ON PLU=ON CHANG J?/AU
`446)SEA ABB=ON PLU=ON POWER D?/AU
`213487)SEA ABB=ON PLU=ON EYE OR ASTHENOPIA OR CONJUNCTIVAL
`DISEASES OR CORNEAL
`
`DISEASES OR EYELID DISEASES
`
`OR LACRIMAL
`APPARATUS DISEASES OR LENS DISEASES OR OCULAR HYPERTENSION
`7948)SEA ABB=ON PLU=ON OCULAR HYPOTENSION OR OCULAR MOTILITY
`DISORDERS OR OPTIC
`NERVE
`
`DISEASES OR ORBITAL DISEASES
`OR PUPIL
`
`DISORDERS OR REFRACTIVE ERRORS OR RETINAL DISEASES
`OR
`SCLERAL DISEASES
`OR
`UVEAL
`DISEASES OR VISION DISORDERS
`
`OR
`VITREORETINOPATHY
`OR
`VITREOUS
`DETACHMENT
`124285)SEA ABB=ON PLU=ON OIL
`23151)SEA ABB=ON PLU=ON EMULSI?
`SEL PLU=ON LI 1- CHEM :
`38 TERMS
`4